A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma. - Kimura,H.; Yamaguchi,Y. (Cancer, 1997)